SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel […]
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company […]
First Quarter Fiscal Year 2025 Highlights: Total revenue of $169.2 million, up 33% year-over-year Significant year-over-year GAAP and Non-GAAP operating […]